AMARIN CORP.ADR LS-50 | 1.560 / -7.14% |
Date/Time | 08/17 / 16:25 |
Chg. / Chg.(%) | -0.120 / -7.14% |
Bid | 1.580 / 1901 |
Ask | 1.625 / 1845 |
Open | 1.560 |
Previous Close | 1.680 |
High | 1.560 |
Low | 1.560 |
Volume [EUR] | 499.200 |
Volume [Units] | 320 |
Price fixings | 1 |
ISIN | US0231112063 |
Security | EH3A |
Exchange | TradeGate |
Type | Stock |
Other Exchanges
Exchange | Last | Volume | |
---|---|---|---|
Lang & Schwa.. | 1.540 | ![]() |
|
NASDAQ | 1.6300 | ![]() |
2,730,930 |
Cboe US | 1.63 | ![]() |
164,612 |
IEX | 1.63 | ![]() |
81,118 |
Frankfurt | 1.5550 | ![]() |
500 |
TradeGate | 1.560 | ![]() |
320 |
Berlin | 1.565 | ![]() |
0 |
München | 1.565 | ![]() |
0 |
Düsseldorf | 1.580 | ![]() |
0 |
Stuttgart | 1.590 | ![]() |
0 |
Quotrix | 1.6150 | ![]() |
|
gettex | 1.5850 | ![]() |
News
- Amarin Receives Reimbursement for VAZKEPA® in Sweden
03/28/2022 / 13:00 - GlobeNewswire - Latest Research Evaluating VASCEPA® (Icosapent Ethyl) to be Presented at the American College of Cardiology’s 71st Annual Scientific Session
03/21/2022 / 13:30 - GlobeNewswire - Latest analysis shows VASCEPA® (icosapent ethyl) significantly lowered the risk of potentially fatal cardiovascular events in patients with prior percutaneous coronary intervention
03/10/2022 / 14:47 - GlobeNewswire - Amarin to Participate in Cowen 42nd Annual Health Care Conference
02/25/2022 / 14:00 - GlobeNewswire - JAMA Publication Highlights VASCEPA® (Icosapent Ethyl) Cardiovascular Risk Reduction Extends to Cost Effectiveness at Patient Level
02/24/2022 / 13:30 - GlobeNewswire
Personal area
Click on
to activate push quotes.
